Purging of Autografts: Methods and Clinical Significance

References

• Gianni A, Siena S, Bregni M, et al. Granulocytemacrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–4
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruehauf S, et al. Patients' characteristics associated with successful mobilizing and auto-grafting of peripheral blood progenitor cells (PBPC) in malignant lymphoma. Blood 1994; 83: 3787–94
   PubMed Web of Science ®Google Scholar
• Bensinger W, Abbelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–55
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplantations for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–96
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J O. Clinical application of hematopoietic growth factors. Blood 1995; 13: 1023–35
   Google Scholar
• Eaves C J. Peripheral blood stem cells reach new heights. Blood 1993; 82: 1957–9
   PubMedGoogle Scholar
• Gribben J G, Freedman A S, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 28: 1525–33
   Google Scholar
• Brenner M K, Rill D R, Moen R C, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–6
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Zu Z, Claxton D, et al. Genetic marking shows that Ph + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–76
   PubMed Web of Science ®Google Scholar
• Moss T J, Ross A A. The risk of tumour cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225–32
   PubMedGoogle Scholar
• Moss T J, Sanders D G, Lasky L C, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879–83
   PubMed Web of Science ®Google Scholar
• Ross A A, Cooper B W, Lazarus H M, et al. Detection and viability of tumour cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–10
   PubMed Web of Science ®Google Scholar
• Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994; 3: 315–22
   PubMedGoogle Scholar
• Diel I J, Kaufmann M, Goerner R, Costa S D, Kaul S, Bastert G. Detection of tumour cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992; 10: 1534–9
   PubMed Web of Science ®Google Scholar
• Shpall E J, Jones R B. Release of tumour cells from bone marrow. Blood 1994; 83: 623–35
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumour cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumours. Blood 1994; 83: 636–40
   PubMed Web of Science ®Google Scholar
• Gribben J G, Neuberg D, Freedman A S, et al. Detection by polymerase chain reaction of residual cells with bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–57
   PubMed Web of Science ®Google Scholar
• Negrin R S, Pesando J. Detection of tumour cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J Clin Oncol 1994; 12: 1021–7
   PubMed Web of Science ®Google Scholar
• Corradini P, Voena C, Astolfi M, et al. High dose sequential chemotheray in multiple myeloma: residual tumour cells are detectable in bone marrow and peripheral blood cell harvest and after autografting. Stood 1995; 85: 1596–602
   Google Scholar
• Datta Y H, Adams P T, Drobyski W R, Ethier S P, Terry V H, Roth M S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475–82
   PubMed Web of Science ®Google Scholar
• Sharp J G, Mann S L, Murphy B, Weekes C. Culture methods for the detection of minimal tumour contamination of hematopoietic harvests: a review. J Hematother 1995; 4: 141–8
   PubMedGoogle Scholar
• Yeager A M, Wiley J M, Jones R, et al. Pharmacologic treatment of bone marrow to eliminate clonogenic tumour cells: laboratory and clinical studies. Bone Marrow Transplant 1987; 2: 34–42, Suppl 2
   Google Scholar
• Jones R, Sharkis S, Colvin M. CFU-GM, CFU-S, predict repopulation ability of in vitro drug treated murine bone marrow. Exp Hematol 1986; 14: 438
   Google Scholar
• Kaizer H, Stuart R K, Brookmeyer R, et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxy-cyclophosphamide to purge tumour cells. Blood 1985; 65: 1504–10
   PubMed Web of Science ®Google Scholar
• Douay L, Gorin N C, Laporte J-P, et al. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 1984; 2: 187–90
   PubMed Web of Science ®Google Scholar
• Rowley S D, Jones R J, Piantadosi S, et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501–6
   PubMed Web of Science ®Google Scholar
• Gorin N C, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in remission: decreased risk of relapse associated with marrow purging by mafosfamide. Blood 1990; 8: 1606–14
   Google Scholar
• Labopin M, Gorin N C. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe; a retrospective study. Leukemia 1992; 6: 95, Suppl 4
   PubMed Web of Science ®Google Scholar
• Ritz J, Pesando J M, Notis-Mc Conarty J, Lazaarus H, Schlossman S. F. A monoclonal antibody to the human acute lymphoblastic leukemia antigen. Nature 1980; 283: 585–7
   PubMedGoogle Scholar
• Ritz J, Sallan S E, Bast R C, et al. Autologous bone marrow transplantation in cALLA-positive acute lymphoblastic leukaemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 1982; ii: 60–3
   Google Scholar
• Bast R C, De Fabritils P, Lipton J, et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• Winter J N, Marder R J, Mankad B, Epstein A L. Heterogeneity among the non-Hodgkin's lymphomas. Cancer 1988; 61: 1082–90
   PubMedGoogle Scholar
• Bast R C, Montogomery R B, Haleem J, et al. Bone marrow purging with antibody and complement: an American review. Bone Marrow Transplant 1987; 2: 58–65, Suppl 2
   Google Scholar
• Ball E D. In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplant 1988; 3: 387–92
   PubMedGoogle Scholar
• Janossy G, Campana D, Amlot P. Application of cytolytic monoclonal antibodies and complement in autologous bone marrow transplantation (BMT). Bone Marrow Transplant 1987; 2: 66–73, Suppl 2
   Google Scholar
• Gee A P, Boyle M DP. Purging tumour cells from bone marrow by use of antibody and complement: a critical appraisal. J Natl Cancer Inst 1988; 80: 154–9
   PubMedGoogle Scholar
• Uhr J W. Immunotoxins: harnessing nature's poisons. J Immunol 1984; 133: i–x
   PubMed Web of Science ®Google Scholar
• Vitetta E S, Uhr J W. Immunotoxins: redirecting nature's poisons. Cell 1985; 41: 653–4
   PubMed Web of Science ®Google Scholar
• Olsnes S, Pihl A. Chimeric toxins. Pharmacol Ther 1982; 15: 335–81
   Google Scholar
• Blakey D C, Thorpe P E. An overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunoconjug Radiopharmaceut 1988; 1: 1–16
   Google Scholar
• Stong R C, Uckun F, Youle R J, Kersey J H, Vallera D A. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 1985; 66: 627–35
   PubMed Web of Science ®Google Scholar
• Casellas P, Canat X, Fauser A A, et al. Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin. Blood 1985; 65: 289–97
   PubMed Web of Science ®Google Scholar
• Uckun F M, Kersey J H, Vallera D A, et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–33
   PubMed Web of Science ®Google Scholar
• Fodstad Ø, Kvalheim G, Pihl A, Godal A, Funderud S. New indirect approach to the therapeutic use of immunotoxins. J Natl Cancer Inst 1988; 80: 439–43
   PubMedGoogle Scholar
• Bjom M J, Manger R, Sivam G, Morgan AC, Jr, Torok-Storb B. Selective elimination of breast cancer cells from human bone marrow using an antibody-pseudomonas exotoxin A conjugate. Cancer Res 1990; 50: 5992–6
   PubMedGoogle Scholar
• Bjorn M J, Groetsema G, Scalapino L. Antibody-pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 1986; 46: 3262–7
   PubMedGoogle Scholar
• Myklebust A T, Godal A, Pharo A, Juell S, Fodstad O. Eradication of small cell lung cancer cells from human bone marrow with immunotoxins. Cancer Res 1993; 53: 3784–8
   PubMedGoogle Scholar
• Myklebust A T, Godal A, Juell S, Pharo A, Fodstad O. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 1994; 54: 209–14
   PubMedGoogle Scholar
• Treleaven J G, Gibson F M, Ugelstad J, et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1: 70–3
   PubMed Web of Science ®Google Scholar
• Kvalheim G, Fodstad Ø, Pihl A, et al. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies. Cancer Res 1987; 47: 846–51
   PubMed Web of Science ®Google Scholar
• Kvalheim G, Funderud S, Kvaløy S, et al. Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. J Natl Cancer Inst 1988; 80: 1322–5
   PubMedGoogle Scholar
• Kvalheim G, Sørensen O, Fodstad Ø, et al. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 1988; 3: 31–41
   PubMed Web of Science ®Google Scholar
• Wang M Y, Kvalheim G, Kvaløy S, et al. An effective immunomagnetic method for bone marrow purging in T cell malignacies. Bone Marrow Transplant 1992; 9: 319–23
   PubMedGoogle Scholar
• Ogniben E, Hohaus S, Kvalheim G, Dorken H, Haas R. Successful autologous transplantation of immunomagnetic bead purged bone marrow in non-Hodgkin's lymphoma. Prog Clin Biol Res 1992; 377: 189–95
   PubMedGoogle Scholar
• Kvalheim G, Jakobsen E, Holte H, et al. Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged with immunomagnetic beads. Adv Bone Marrow Purg Process 1994; 133–8
   Google Scholar
• Kiesel S, Haas R, Moldenhauer G, Kvalheim G, Pezzutto A, Dorken B. Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis. Leukemia Res 1987; 11: 1119–25
   PubMed Web of Science ®Google Scholar
• Straka C, Dorken B, Kvalheim G. Polymerase chain reaction monitoring shows a high efficacy of clinical immunomagnetic purging in patients with centroblastic-centrocytic non-Hodgkin's lymphoma. Blood 1992; 15: 2688–90
   Google Scholar
• Deggerdal A H, Pettersen F, Kvalheim G, et al. Semiquantitative polymerase chain reaction for t(14;18) in follicular lymphomas: a colorimetric approach. Lab Invest 1995; 4: 1–7
   Google Scholar
• Sphall E J, Jones R J, Bearmenn S I, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28–36
   PubMedGoogle Scholar
• Dunbar C E, Cottier-Fox M, O'Shaughnessy J A. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048–57
   PubMed Web of Science ®Google Scholar
• Smeland E B, Funderud S, Kvalheim G, et al. Isolation and characterization of human hematopoietic progenitor cells: an efficient method for positive selection of CD34 + cells. Leukemia 1992; 6: 845–52
   PubMedGoogle Scholar
• Eaves C J, Cashman J D, Eaves A C. Methodology of long-term culture of human hematopoietic cells. J Tissue Cult Methods 1991; 13: 55–61
   Google Scholar
• Coulombel L, Kalousek D K, Eaves C J, Gupta C M, Eaves A C. Long-term marrow culture reveals chromosomal normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493–8
   PubMed Web of Science ®Google Scholar
• Testa N G, Dexter M T. The biology of long-term bone marrow cultures and its application to bone marrow transplantation. Curr Opinion Oncol 1991; 3: 272–8
   PubMedGoogle Scholar
• Udomsakdi C, Eaves C J, Swolin B, Reid D S, Barnett M J, Eaves A C. Rapid decline of chronic myeloid cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192–6
   PubMed Web of Science ®Google Scholar
• Brugger W, Heimfeld S, Berenson R J, Mertelsman R, Kanz L. Reconstitution of hematopoieses after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995; 333: 283–7
   PubMed Web of Science ®Google Scholar
• Ayash L J, Elias A, Wheeler C, et al. Double dose intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37–44
   PubMed Web of Science ®Google Scholar